J&J to begin human trials of Covid-19 vaccine in second half of July

J&J's study will test the vaccine against a placebo and assess the shot's safety and immune response in 1,045 healthy people aged 18 to 55 years
Johnson & Johnson said on Wednesday it would start human trials of its potential Covid-19 vaccine in the second half of July, two months earlier than planned, as drugmakers race to develop a shot for the deadly respiratory disease.

The company has already signed deals with the US government to create enough manufacturing capacity to produce more than 1 billion doses of its vaccine through 2021.

 
There are currently no approved treatments or vaccines for Covid-19, the illness caused by the new coronavirus that has killed more than 400,000 people globally.

J&J's study will test the vaccine against a placebo and assess the shot's safety and immune response in 1,045 healthy people aged 18 to 55 years, as well as those 65 years and older.

The trial will take place in the United States and Belgium.

US biotech Moderna Inc is at the forefront of Covid-19 vaccine development and has started testing its candidate in a mid-stage trial that will enroll 600 patients.

 
The company expects to begin late-stage trials in July.

AstraZeneca, Sanofi, Pfizer and GlaxoSmithKline are all at various stages of development of their vaccine candidates.

There are currently about 10 coronavirus vaccines being tested in humans and experts have predicted that a safe and effective vaccine could take 12 to 18 months from the start of development.


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel